DUBLIN, May 11, 2023 /PRNewswire/ -- The "Global Central Nervous System Partnering 2016-2023: Deal trends, players and financials" report has been added to
Global Central Nervous System Partnering 2016 to 2010 provides the full collection of central nervous system disease deals signed between the world's pharmaceutical and biotechnology companies since 2016.
Trends in central nervous system partnering deals
Financial deal terms for headline, upfront and royalty by stage of development
Central Nervous System partnering agreement structure
Central Nervous System partnering contract documents
Top central nervous system deals by value
Most active central nervous system dealmakers
Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.
The report takes readers through the comprehensive central nervous system disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering central nervous system deals.
The report presents financial deal terms values for central nervous system deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.
The initial chapters of this report provide an orientation of central nervous system dealmaking trends.
Chapter 1 provides an introduction to the report.
Chapter 2 provides an overview of the trends in central nervous system dealmaking since 2016 covering trends by year, deal type, stage of development, technology type and therapeutic indication.
Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates.
Chapter 4 provides a review of the leading central nervous system deals since 2016. Deals are listed by headline value. The chapter includes the top 25 most active central nervous system dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
Chapter 5 provides comprehensive access to central nervous system deals since 2016 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.
Chapter 6 provides a comprehensive directory of all central nervous system partnering deals by specific central nervous system target announced since 2016. The chapter is organized by specific central nervous system therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
In addition, a comprehensive appendix is provided with each report of all central nervous system partnering deals signed and announced since 2016. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
The report also includes numerous tables and figures that illustrate the trends and activities in central nervous system partnering and dealmaking since 2016.
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of central nervous system technologies and products.
Global Central Nervous System Partnering 2016 to 2023 is intended to provide the reader with an in-depth understanding and access to central nervous system trends and structure of deals entered into by leading companies worldwide.
Global Central Nervous System Partnering 2016 to 2023 includes:
Trends in central nervous system dealmaking in the biopharma industry since 2016
Access to headline, upfront, milestone and royalty data
Access to hundreds of central nervous system deal contract documents
Comprehensive access to over 1,700 central nervous system deal records
The leading central nervous system deals by value since 2016
Most active central nervous system dealmakers since 2016
The report includes deals for the following indications: Cerebral palsy, Creutzfeldt Jakob disease, Dizziness, Epilepsy, Faints, Falls, Guillain Barre syndrome, Headache, Meningitis (Bacterial, Meningococcal, Pneumococcal), Mycobacterium tuberculosis (TB), Haemophilus influenzae Type B (Hib), Migraine, Motor Neurone Disease (Amyotrophic Lateral Sclerosis/Lou Gehrig's Disease, Multiple sclerosis, Nausea, Neuropathy, Pain, Neuralgia, Fibromyalgia, Paralysis, Parkinson's disease, Restless leg syndrome, Spinal cord, Stroke, Stuttering, Traumatic Brain Injury, Vertigo, Weakness, plus other CNS indications.
In Global Central Nervous System Partnering 2016 to 2023, available deals and contracts are listed by:
Upfront payment value
Royalty rate value
Stage of development at signing
Deal component type
Specific therapy indication
Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
The Global Central Nervous System Partnering 2016-2023 report provides comprehensive access to available deals and contract documents for over 1,700 central nervous system deals.
Analyzing actual contract agreements allows assessment of the following:
What are the precise rights granted or optioned?
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What is the payment structure for the deal?
How are the sales and payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?
Selection of Companies Mentioned
3M Drug Delivery Systems
A*STAR Agency for Science
Technology and Research
Aarhus University Hospital
Accelerated Cure Project for MS
Actavis (acquired by Watson)
Advanced Cooling Therapy
Advanced Technologies Solutions
Advantage Consumer Healthcare
AKC Canine Health Foundation
Albany Molecular Research
Alberta Health Services
Albert Einstein College of Medicine
Allen Institute for Brain Science
Allergan (name changed from Actavis)
Allied Healthcare Products
ALS Finding a Cure Foundation
Alzheimer's Drug Discovery Foundation
Alzheimers Research UK
American Academy of Neurology
American Association of Neuromuscular & Electrodiagnostic Medicine
American College of Emergency Physicians
American College of Physicians Foundation
American Heart/Stroke Association
American Heart Association
American Migraine Foundation
American National Multiple Sclerosis Society
American Parkinson Diseases Association
American Speech-Language-Hearing Association
Analytical Testing Laboratory
Anavex Life Sciences
Annette Funicello Research Fund for Neurological Diseases (AFRFND)
APR Applied Pharma Research
Arizona State University
Association for Frontotemporal Degeneration
Astellas Pharma Europe
ATAI Life Sciences
Biomarker & Lifestyle Flagship Study of Ageing (AIBL)
Australian Research Council
Bachmann-Strauss Dystonia & Parkinson Foundation
Baylor College of Medicine
Beijing Leadman Biochemistry
Beyond Batten Disease Foundation
Biohaven Pharmaceutical Holding
Bioinn Molecular Diagnosis
Biomedical Advanced Research and Development Authority
BioMed X Innovation Center
Bioscience Pharma Partners
Boston University School of Medicine
Brain and Spine Institute
BrainStorm Cell Therapeutics
Brain Treatment Center San Diego
Brigham and Women's Hospital
California Institute for Biomedical Research
California Institute for Regenerative Medicine
California Institute of Technology
Calox de Costa Rica
Camargo Pharmaceutical Services
Canadian Institutes of Health Research
Canadian Physiotherapy Association
Cellular Dynamics International
Center for iPS Cells Research and Application
Center for Sensorimotor Neural Engineering
Center for Technology and Innovation in Pediatrics (CTIP)
Center for the Advancement of Science in Space
Centre for Commercialization of Regenerative Medicine (CCRM)
Centre for Drug Research and Development (CDRD)
Centre Hospital University - Bordeaux
Centro de Investigacion Biomedica en Red de Salud Mental
Charles River Associates
Charles River Laboratories
Children's Hospital Boston
Children's Hospital of Pittsburgh Foundation
Children's Hospital Of Wisconsin
Children's Research Institute
Christopher & Dana Reeve Foundation
Cincinnati Children's Hospital Medical Center
Citizens United for Research in Epilepsy
City of Hope
Cleveland Diabetes Care
Clinical Laserthermia Systems (CLS)
Clinical Network Services
Cohen Veterans Bioscience
Columbia University Medical Center
Compassionate Care Center of New York
Compass Point Research
Congressman Chaka Fattah
Courtagen Life Sciences
CSPC Pharmaceutical Group
Department of Defense
Department of Health and Human Services
Department of Veterans Affairs
Dr. Reddy's Laboratories
Dr. Stephen Cook
Draeger Safety Diagnostics
Duke-NUS Graduate Medical School Singapore
DZNE German Center for Neurodegenerative Diseases
Early Signal Foundation
Edith Cowan University (ECU)
EMMAC Life Sciences
Epilepsy Foundation (EF)
European Parkinson's Disease Association
Federal Ministry of Education and Research (BMBF)
Feinstein Institute for Medical Research
Flint Rehabilitation Devices
Florey Institute of Neuroscience and Mental Heath
Florida Atlantic University Research
Food and Drug Administration (FDA)
Foundation For Angelman Syndrome Therapeutics
Foundation for Mitochondrial Medicine
Foundation for the National Institutes of Health (FNIH)
Fresenius Kabi Pharmaceuticals
Fundacion Universidad Torcuato Di Tella
Geisinger Medical Center
General Electric (GE)
Gene Therapy Research Institution
George Washington University
Georgia Institute of Technology
Global Alliance for Innovation in Neuroscience
Global Drug Development Centre (GDCC) China
Gold Coast Therapeutics
For more information about this report visit
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Research and Markets
Laura Wood, Senior Manager
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
SOURCE Research and Markets